Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7585)
All Articles published online
|
Publishing Process of This Article
|
Jun 7, 2015 (publication date) through Apr 18, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Paoluzi OA, Del Vecchio Blanco G, Visconti E, Coppola M, Fontana C, Favaro M, Pallone F. Low efficacy of levofloxacin-doxycycline-based third-line triple therapy for |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i21/6698.htm |
| Number | Citing Articles |
| 1 |
Long-Kuan Yin, Hua-Yan Yuan, Jian-Jun Liu, Xiu-Lian Xu, Wei Wang, Xiang-Yu Bai, Pan Wang. Identification of survival-associated biomarkers based on three datasets by bioinformatics analysis in gastric cancer. World Journal of Clinical Cases 2023; 11(20): 4763-4787 doi: 10.12998/wjcc.v11.i20.4763
Abstract(361) |
Core Tip(180) |
Full Article(HTML)(1241)
|
Full Article with Cover (PDF)-49291K(44)
|
Full Article (Word)-4243K(26)
|
Audio-1362K(0)
|
Peer-Review Report-207K(23)
|
Answering Reviewers-56K(28)
|
Supplementary Material-844K(30)
|
Full Article (PDF)-48011K(131)
|
Full Article (XML)-117K(32)
|
Times Cited (0)
|
Total Visits (4357)
|
Open
|
| 2 |
Pedro Vieira de Moraes Andrade, Yan Mosca Monteiro, Ethel Zimberg Chehter. Third-line and rescue therapy for refractory <i>Helicobacter pylori</i> infection: A systematic review. World Journal of Gastroenterology 2023; 29(2): 390-409 doi: 10.3748/wjg.v29.i2.390
|
| 3 |
Hidekazu Suzuki, Hideki Mori. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. Journal of Gastroenterology 2018; 53(3): 354 doi: 10.1007/s00535-017-1407-1
|
| 4 |
Eskandar Hajiani, Pezhman Alavinejad, Nahid Avandi, Abdol Rahim Masjedizadeh, Ali Akbar Shayesteh. Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial. Middle East Journal of Digestive Diseases 2018; 10(4): 242 doi: 10.15171/mejdd.2018.117
|
| 5 |
Sintayehu Fekadu, Hizkel Engiso, Sisay Seyfe, Hisashi Iizasa, Ashebir Godebo, Serawit Deyno, Hironori Yoshiyama. Effectiveness of eradication therapy for Helicobacter pylori infection in Africa: a systematic review and meta-analysis. BMC Gastroenterology 2023; 23(1) doi: 10.1186/s12876-023-02707-5
|
| 6 |
Anthony O'Connor, Wolfgang Fischbach, Javier P. Gisbert, Colm O'Morain. Treatment of Helicobacter pylori infection 2016. Helicobacter 2016; 21(S1): 55 doi: 10.1111/hel.12342
|
| 7 |
Doxycycline/esomeprazole/levofloxacin. Reactions Weekly 2016; 1601(1): 112 doi: 10.1007/s40278-016-17414-8
|
| 8 |
Majid Eslami, Bahman Yousefi, Parviz Kokhaei, Ali Jazayeri Moghadas, Bizhan Sadighi Moghadam, Vahid Arabkari, Zohreh Niazi. Are probiotics useful for therapy of Helicobacter pylori diseases?. Comparative Immunology, Microbiology and Infectious Diseases 2019; 64: 99 doi: 10.1016/j.cimid.2019.02.010
|
| 9 |
Yue Wang, Xue Wang, Xue-Yan Cao, Han-Long Zhu, Lin Miao. Comparative effectiveness of different probiotics supplements for triple helicobacter pylori eradication: a network meta-analysis. Frontiers in Cellular and Infection Microbiology 2023; 13 doi: 10.3389/fcimb.2023.1120789
|
| 10 |
|
| 11 |
Huo-Ye Gan, Tie-Li Peng, You-Ming Huang, Kai-Hua Su, Lin-Li Zhao, Li-Ya Yao, Rong-Jiao Yang. Efficacy of two different dosages of levofloxacin in curing Helicobacter pylori infection: A Prospective, Single-Center, randomized clinical trial. Scientific Reports 2018; 8(1) doi: 10.1038/s41598-018-27482-2
|
| 12 |
Hideki Mori, Hidekazu Suzuki. Update on quinolone-containing rescue therapies for <i>Helicobacter pylori</i> infection. World Journal of Gastroenterology 2020; 26(15): 1733-1744 doi: 10.3748/wjg.v26.i15.1733
|
| 13 |
Siya Kong, Han Chen, Keting Huang, Duochen Jin, Guoxin Zhang, Feng Ye. Antibiotic susceptibility guided reuse of levofloxacin-based therapy in a penicillin-allergic patient for Helicobacter pylori infection. Medicine 2021; 100(10): e24915 doi: 10.1097/MD.0000000000024915
|
| 14 |
COMPARING THE EFFICACY OF CONCOMITANT THERAPY WITH THE STANDARD TRIPLE REGIMEN AS FIRST LINE THERAPY OF HELICOBACTOR PYLORI ERADICATION. JAIMC: Journal of Allama Iqbal Medical College 2023; 20(2) doi: 10.59058/jaimc.v20i2.38
|
| 15 |
Tommaso Cai, Luca Gallelli, Erika Cione, Gianpaolo Perletti, Francesco Ciarleglio, Gianni Malossini, Giovanni De Pretis, Alessandro Palmieri, Vincenzo Mirone, Riccardo Bartoletti, Truls E. Bjerklund Johansen. The use of Lactobacillus casei DG® prevents symptomatic episodes and reduces the antibiotic use in patients affected by chronic bacterial prostatitis: results from a phase IV study. World Journal of Urology 2021; 39(9): 3433 doi: 10.1007/s00345-020-03580-7
|
| 16 |
Alba A. Trespalacios-Rangél, William Otero, Azucena Arévalo-Galvis, Raúl A. Poutou-Piñales, Emiko Rimbara, David Y. Graham, Massimiliano Galdiero. Surveillance of Levofloxacin Resistance in Helicobacter pylori Isolates in Bogotá-Colombia (2009-2014). PLOS ONE 2016; 11(7): e0160007 doi: 10.1371/journal.pone.0160007
|
| 17 |
Lei Gu, Shenglan Li, Ying He, Yi Chen, Yanzhi Jiang, Yu Peng, Xiaowei Liu, Huixiang Yang. Bismuth, rabeprazole, amoxicillin, and doxycycline as first‐line Helicobacter pylori therapy in clinical practice: A pilot study. Helicobacter 2019; 24(4) doi: 10.1111/hel.12594
|